A6733

Auranofin

≥98% (HPLC), powder, leukocyte activation pathway inhibitor

• Synonim(y): 1-Thio-β-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate, 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium, SKF 39162
• Wzór empiryczny (zapis Hilla): C₂₀H₃₄AuO₉PS
• Numer CAS: 34031-32-8
• Masa cząsteczkowa: 678.48
• Numer WE: 251-801-9
• Numer MDL: MFCD00080759
• Kod UNSPSC: 51111800
• Identyfikator substancji w PubChem: 329770903
• NACRES: NA.77

Właściwości

• Nazwa produktu: Auranofin, ≥98% (HPLC)
• Poziom jakości: 100
• Próba: ≥98% (HPLC)
• Formularz: powder
• rozpuszczalność: DMSO: ≥5 mg/mL
• inicjator: Prometheus
• temp. przechowywania: room temp
• ciąg SMILES: CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
• InChI: 1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1/t10-,11-,12+,13-,14+;;/m1../s1
• Klucz InChI: AUJRCFUBUPVWSZ-XTZHGVARSA-M

Opis

Zastosowanie

Auranofin inhibits both leukocyte activation pathways at multiple sites and the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. Auranofin also inhibits 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5 and selenoenzyme thioredoxin reductase (TrxR) which is involved in the defense against oxidative stress. Auranofin is a disease-modifying antirheumatic drug (DMARD) and has been used to study the anti-proliferative effects against OVCAR-3 human ovarian carcinoma cells.

Działania biochem./fizjol.

Auranofin inhibits various leukocyte activation pathways at multiple sites and is a disease-modifying antirheumatic drug (DMARD).

Auranofin inhibits various leukocyte activation pathways at multiple sites. Auranofin inhibits the release of inflammatory mediators from human macrophages, basophils, and pulmonary mast cells. The compound also inhibits 5-lipoxygenase in human neutrophils. Auranofin is a disease-modifying antirheumatic drug (DMARD). The compound is a potent inhibitor of selenoenzyme thioredoxin reductase (TrxR), which is involved in defense against oxidative stress. Auranofin is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions related to its inhibition of mitochondrial thioredoxin reductase. Auranofin inhibits IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5.

Cechy i korzyści

This compound was developed by Prometheus. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Piktogramy: GHS06,GHS08
• Hasło ostrzegawcze: Danger
• Zwroty wskazujące rodzaj zagrożenia: H301,H361
• Zwroty wskazujące środki ostrożności: P202 - P264 - P270 - P280 - P301 + P310 - P405
• Klasyfikacja zagrożeń: Acute Tox. 3 Oral - Repr. 2
• Kod klasy składowania: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Klasa zagrożenia wodnego (WGK): WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable
• Środki ochrony indywidualnej: dust mask type N95 (US), Eyeshields, Faceshields, Gloves